Government Selling Special Human Cell Line for Virus Research
Published Date: 6/25/2026
Notice
Summary
The National Cancer Institute is offering a special human T-cell line called C8166-45 for licensing. This cell line helps scientists study viruses like HTLV-1 and HIV, which can cause serious diseases. Researchers and companies can now use this tool to develop better treatments, with licensing info available starting June 2026—no patents, just pure science power ready to roll!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
C8166-45 Available for Licensing
The National Cancer Institute is offering the human T‑cell line C8166-45 (NIH Reference Number E-272-2007) for non-exclusive licensing. The product is fully developed, listed as Research Material/Tool, and Patents: N/A; inquiries are directed to Diptadip Dattaroy, Ph.D., phone 240-276-7092 (Dated: June 23, 2026).
Tool for Gene Therapy Safety Testing
The C8166-45 cell line is highly permissive to HIV-1 infection and is characterized as suitable for replication-competent lentiviral (RCL) assays to assess safety of gene therapy products such as lentiviral vectors. NCI highlights its use for studying HTLV-1 and HIV biology and for testing RCL assay sensitivity (NIH Reference Number E-272-2007).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20705, Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof
The National Institute of Allergy and Infectious Diseases plans to give Korea National Institute of Health an exclusive license to develop and sell a special antibody that targets a dangerous virus causing severe fever and low platelets. This deal helps speed up turning the invention into real-world treatments. Comments or license requests must be sent by October 26, 2026.
2026-20424, National Cancer Institute; Notice of Meeting
The President's Cancer Panel is holding a free virtual meeting on October 15, 2026, to talk about how GLP-1 medications can help lower cancer risks linked to obesity. Anyone interested can join online or send in comments beforehand. This meeting is a great chance for patients, doctors, and researchers to learn about new ways to fight cancer and improve health.
2026-20365, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings on October 29-30, 2026, to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like biochemistry, software engineering, and mental health will be affected, with no direct money changes announced but important decisions coming soon.
2026-20151, Notice of NIH Tribal Consultations and Listening Session
The NIH is inviting Tribal leaders and members to join two important meetings and a listening session during the National Congress of American Indians Annual Convention in October 2026. They’ll talk about new health research projects, renewing support for Tribal health centers, and shaping a new Tribal Data Sovereignty Policy. Tribes can also send their thoughts by November 20, 2026, helping shape future health programs and policies.
2026-19719, Center for Scientific Review; Amended Notice of Meeting
The NIH’s Center for Scientific Review is shortening a key meeting from two days to just one day on October 13, 2026, keeping the same 9 a.m. to 6 p.m. hours. This change affects members of the Surgical Sciences and Bioengineering review group and means less time in the room but no public access. No money changes or delays are expected—just a quicker, tighter meeting!
Previous / Next Documents
Previous: 2026-12842, Government Owned Inventions Available for License: Compositions and Methods for Producing Dendritic Cell-based Vaccines With Enhanced Efficacy
The National Cancer Institute has created a new way to make cancer vaccines stronger by using special omega-3 fats to boost immune cells called dendritic cells. This could help scientists and companies develop better cancer treatments that work more effectively. If you’re in biotech or medicine, now’s the time to team up or license this exciting technology and help bring improved vaccines to patients faster.
Next: 2026-12844, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings on July 17, 2026, to review important grant applications. These meetings protect private info and trade secrets while deciding which science projects get funding. Researchers applying for grants in brain injury, neurobehavior, nanotech, and heart/lung studies should note these review dates and prepare accordingly.